Loading…
Lexaria Bioscience Corp. is projected to rise to $0.7698 by 2027, a +19% move from its current price of $0.6466. LEXX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $0.6186 | $0.6462 | $0.6751 | -0.06% |
| Jul 13 | $0.6071 | $0.6459 | $0.6871 | -0.11% |
| Jul 14 | $0.5984 | $0.6455 | $0.6963 | -0.17% |
| Jul 15 | $0.5911 | $0.6451 | $0.7041 | -0.23% |
| Jul 16 | $0.5847 | $0.6447 | $0.711 | -0.29% |
| Jul 17 | $0.5789 | $0.6444 | $0.7172 | -0.34% |
| Jul 18 | $0.5736 | $0.644 | $0.723 | -0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.5736 | $0.644 | $0.723 | -0.40% |
| Week 2 | $0.5446 | $0.6414 | $0.7554 | -0.80% |
| Week 3 | $0.5228 | $0.6388 | $0.7806 | -1.20% |
| Week 4 | $0.5048 | $0.6363 | $0.8019 | -1.60% |
| Week 5 | $0.4893 | $0.6337 | $0.8208 | -1.99% |
| Week 6 | $0.4754 | $0.6312 | $0.838 | -2.38% |
| Week 7 | $0.4629 | $0.6286 | $0.8538 | -2.78% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lexaria Bioscience Corp. is a biotechnology company that offers its patented DehydraTECH drug delivery platform. The technology combines active pharmaceutical ingredients with specific long-chain fatty acid-rich triglyceride oils and carrier compounds to improve how they enter the bloodstream, increasing their effectiveness and enabling lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.
DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose-dependent insulinotropic peptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. The technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; it is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods.
The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Lexaria Bioscience Corp. (LEXX) operates in the Healthcare sector. The current price is $0.615 and its market capitalization is $15.24M, with a rank of 5008.
The stock displays a bullish technical backdrop, with a current price around the $0.615 area and a 30-day technical picture that supports further upside potential. Forecasts show upside potential over a multi-year horizon, with the 2026–2050 outlook detailing rising averages and sizable max-price opportunities.
A major floor 26.2% below — a decisive break under it would weaken the trend.
The nearest floor, 18.0% below — buyers have tended to step in here.
The nearest ceiling, 3.3% above — a clean break opens room to run.
A major ceiling 63.9% above — clearing it would confirm fresh momentum.
Key LEXX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LEXX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.5914 | Buy | $0.6052 | Buy |
| MA 10 | $0.5748 | Buy | $0.5892 | Buy |
| MA 20 | $0.5798 | Buy | $0.5897 | Buy |
| MA 50 | $0.6097 | Buy | $0.6328 | Buy |
| MA 100 | $0.7109 | Sell | $0.6946 | Sell |
| MA 200 | $0.805 | Sell | $0.8228 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.92 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 152.36 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 13.91 | Buy |
| Bollinger %B (20,2) | 0.99 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.49 | Sell |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 69.94 | Neutral |
| Momentum (10) | 0.10 | Buy |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 0.62 | Buy |
| ADX (14) | 15.82 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is BULLISH, with RSI(14) at 50. SMA-50 is $0.6144 and SMA-200 is $0.8085. The price sits above support at $0.53 and below resistance at $0.668. The 30-day price range runs from $0.4609 to $0.8205.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.53 | $0.6466 | $0.7816 | 0% | Neutral | |
| $0.5786 | $0.7698 | $1.10 | +19% | Neutral | |
| $0.6121 | $0.8542 | $1.29 | +32% | Bullish | |
| $0.7003 | $1.02 | $1.60 | +57% | Bullish | |
| $0.7195 | $1.08 | $1.77 | +68% | Bullish | |
| $0.6657 | $1.04 | $1.74 | +60% | Bullish | |
| $0.6688 | $1.08 | $1.86 | +66% | Bullish | |
| $0.6132 | $1.02 | $1.80 | +57% | Bullish | |
| $0.6852 | $1.17 | $2.11 | +81% | Bullish | |
| $0.8933 | $1.57 | $2.89 | +142% | Bullish | |
| $0.8655 | $1.73 | $3.48 | +168% | Bullish | |
| $1.87 | $4.15 | $9.39 | +542% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.53 | $0.6466 | $0.7535 | +0.00% |
| August 2026 | $0.4945 | $0.5934 | $0.7381 | -8.22% |
| September 2026 | $0.5055 | $0.6136 | $0.7764 | +3.40% |
| October 2026 | $0.5018 | $0.6151 | $0.7897 | +0.25% |
| November 2026 | $0.4724 | $0.5839 | $0.7586 | -5.08% |
| December 2026 | $0.4776 | $0.595 | $0.7816 | +1.90% |
Click any year to see its month-by-month LEXX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, LEXX is projected to trade between $0.53 and $0.7816, averaging $0.6466 — a potential gain of 0% from today's $0.6466. Price action looks broadly range-bound.
Lexaria Bioscience Corp.'s 2027 outlook centres on $0.7698, within a $0.5786 to $1.10 range. That is up +19% on the projected 2026 average. That marks a +19% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, LEXX could reach as high as $1.29, with a base case around $0.8542 and support toward $0.6121 — roughly +32% from $0.6466. Momentum favours further upside here.
Expect LEXX to range from $0.7003 to $1.60 through 2029. The $1.02 average target implies a +57% move from current prices. That is up +19% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The LEXX price prediction for 2030 points to an average of $1.08 (low $0.7195, high $1.77) — a potential gain of +68% on today's $0.6466. Momentum favours further upside here.
In 2031, LEXX is projected to trade between $0.6657 and $1.74, averaging $1.04 — a potential gain of +60% from today's $0.6466. That is -4% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
Lexaria Bioscience Corp.'s 2032 outlook centres on $1.08, within a $0.6688 to $1.86 range. That is up +4% on the projected 2031 average. That marks a +66% change versus current levels. Momentum favours further upside here.
By 2033, LEXX could reach as high as $1.80, with a base case around $1.02 and support toward $0.6132 — roughly +57% from $0.6466. Buyers look set to stay in control over this stretch.
Expect LEXX to range from $0.6852 to $2.11 through 2034. The $1.17 average target implies a +81% move from current prices. That is up +15% on the projected 2033 average. Momentum favours further upside here.
The LEXX price prediction for 2035 points to an average of $1.57 (low $0.8933, high $2.89) — a potential gain of +142% on today's $0.6466. Buyers look set to stay in control over this stretch.
In 2040, LEXX is projected to trade between $0.8655 and $3.48, averaging $1.73 — a potential gain of +168% from today's $0.6466. That is up +11% on the projected 2035 average. Momentum favours further upside here.
Lexaria Bioscience Corp.'s 2050 outlook centres on $4.15, within a $1.87 to $9.39 range. That is up +139% on the projected 2040 average. That marks a +542% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in LEXX today (≈ 1,546.551191 LEXX) could be worth
$6,418.08
+$5,418.08 (+542%) by 2050 · US Dollar
Based on the average projected LEXX price of $4.15 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LEXXwould be worth at today's price.
$1,000 invested in LEXX on Jul 10, 2025 (≈ 1,111.111141 LEXX) would be worth
$718.44
-$281.56 (-28.2%) today · 0.72× · US Dollar
Based on a LEXX entry price of $0.9 vs. today's $0.6466.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.56 | $1,154.64 | +15.5% |
| 1 month ago | $0.656 | $985.67 | -1.4% |
| 3 months ago | $0.91 | $710.55 | -28.9% |
| 6 months ago | $0.77 | $839.74 | -16.0% |
| 1 year ago | $0.9 | $718.44 | -28.2% |
| All time (5.0y) ago | $7.07 | $91.46 | -90.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LEXX forecast.
Our base-case forecast reaches $1.30 around 2035.
Implied market cap at $1.30: $32.22M
Multi-year forecasts indicate an overall bullish trajectory, with 2026 showing a neutral stance (min $0.53, avg $0.615, max $0.7413; roiPct 0) and steady movement higher in subsequent years. By 2030, the avg price is forecast at $1.01 with a max of $1.64 (roiPct 63.7, sentiment BULLISH); by 2035, max reaches $2.62 (roiPct 130.7). The path continues with 2040 max $3.13 and 2050 max $8.39 (roiPct 153.7 in 2040 and 502.5 in 2050; sentiment BULLISH across these years).
The long-term view shows an avg of $3.71 by 2050, underscoring a strong upside potential, but these are estimates and not guarantees.
Tap a question to reveal the answer.
Avg price $1.01, min $0.668, max $1.64, roiPct 63.7.
Forecasts show neutral sentiment in 2026 and 2027, then bullish conditions from 2028 onward, with avg rising to $3.71 by 2050 and ROI up to 502.5%.
Yes. The max forecast reaches $2.62 by 2035, with higher maxima of $3.13 by 2040 and $8.39 by 2050.
Current price $0.615; market cap $15.24M.
Low $0.4609; High $0.8205.
Lexaria Bioscience Corp. Community Discussion
0Share your Lexaria Bioscience Corp. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.